Lv4
720 积分 2026-04-19 加入
Unraveling cellular and molecular mechanisms of relapse in CD19/CD22 dual-targeting chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia
4小时前
已完结
Real-World Outcomes with BCMA- and GPRC5D-Targeting Bispecific Antibodies in Plasma Cell Leukemia
10天前
已关闭
Concurrent administration of BCMA and GPRC5D chimeric antigen receptor (CAR) T cells in advanced multiple myeloma
11天前
已完结
Sequential CAR T-cell therapy in myeloma: going from BCMA to GPRC5D
20天前
已完结
Long-term analysis of cellular immunity in patients with RRMM treated with CAR-T cell therapy
27天前
已完结
Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy
1个月前
已完结
Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma: A US subgroup analysis from MagnetisMM‐3
1个月前
已完结
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins
1个月前
已完结
The bone marrow NK-cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy
3个月前
已完结
Mechanisms of CD8+ T cell exhaustion and its clinical significance in prognosis of anti-tumor therapies: A review
3个月前
已完结
皖公网安备34019202002308
